Drugmaker Moderna Inc. sent out its first batch of a experimental coronavirus vaccine to be tested in humans; eptinezumab, sold as Vyepti and developed by Lundbeck, was approved by the FDA as a migraine prevention therapy; a US appeals court upheld a Trump administration rule on abortion referrals.
Yesterday, drugmaker Moderna Inc. shipped the first batch of its developed coronavirus vaccine to US government researchers who will then test its efficacy for the first time in a human cohort trial, according to The Wall Street Journal. The vaccine was rapidly developed by the manufacturers in 3 months and will be tested on 20-25 healthy volunteers in April to determine whether 2 doses will be safe and generate an immune response to protect against infection. Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, said that results will be available in July or August.
Eptinezumab, sold as Vyepti and developed by drugmaker Lundbeck, was approved by the FDA as a migraine prevention therapy, adding to the available class of biologic drugs that are laboratory-produced molecules engineered to serve as substitute disease-fighting antibodies. Reuters reports that the drug will be administered via intravenous infusion; it works to inhibit the calcitonin gene-related peptide, a known catalyst for migraine pain development.
The US 9th Circuit Court of Appeals ruled Monday to uphold a 2019 Trump administration rule that denies family planning grants to clinics that make referrals for abortion, according to the Los Angeles Times. The decision additionally overturned injunctions issued by different judges in 3 Western states, including California. The split 7-4 party line ruling was an en banc review, which means all of the district court judges have a chance to weigh in on a previous decision rendered by a 3-judge panel. Since taking office, President Trump has been actively replacing federal judges with those with Republican backgrounds.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Team Coordination, Data Sharing Help Prioritize Value in Cardio-Renal-Metabolic Care
September 12th 2025Cardiologists, nephrologists, and payers met in Scottsdale, Arizona, on August 26, 2025, to share insights on how team members can work together, empowered by data, to achieve value-based management of cardio-renal-metabolic syndrome.
Read More
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Team Coordination, Data Sharing Help Prioritize Value in Cardio-Renal-Metabolic Care
September 12th 2025Cardiologists, nephrologists, and payers met in Scottsdale, Arizona, on August 26, 2025, to share insights on how team members can work together, empowered by data, to achieve value-based management of cardio-renal-metabolic syndrome.
Read More
2 Commerce Drive
Cranbury, NJ 08512